CIP
TEVA icon

Capital Insight Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Insight Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,617
Closed -$895K – 167
2024
Q4 		$895K Buy
40,617
+26,617
+190% +$484K 0.15% 104
2024
Q3 		$252K Buy
+14,000
New +$245K 0.04% 147

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Capital Insight Partners's TEVA Position: Q1 2025 in Review

Capital Insight Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 40,617 shares — an estimated $895K sold.

Capital Insight Partners first reported a position in TEVA in Q3 2024 and held it in 2 quarters. The position peaked at $895K in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Capital Insight Partners reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Capital Insight Partners sold 40,617 Teva Pharmaceuticals shares in Q1 2025, an estimated $895K.
  • Capital Insight Partners first reported a position in Teva Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Capital Insight Partners's Teva Pharmaceuticals position peaked at $895K in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Capital Insight Partners's 13F filing for Q1 2025, filed 30 Apr 2025.